Good Morning Egypt 10 8 2026 Dr Amal El Kady

Main ideas, concepts, and lessons

Purpose of the episode

• The segment highlights certain diseases and discusses Egypt’s role in the health sector in Africa, with a focus on autoimmune skin diseases.

Egypt’s involvement / regional activity

• Egypt is portrayed as playing a pivotal role in regional healthcare and as helping move the health sector toward development.
• Dr. Amal El-Qadi mentions upcoming lectures in South Africa on autoimmune skin diseases, specifically:
  • Vitiligo
  • Alopecia

What autoimmune skin diseases are (core explanation)

• Definition: Autoimmune skin diseases happen when the immune system mistakenly attacks healthy skin cells, leading to:
  • Inflammation
  • Tissue destruction
  • Visible skin lesions
• Examples mentioned:
  • Psoriasis
  • Alopecia areata (hair loss)
  • Vitiligo
  • Pemphigus vulgaris
  • Systemic lupus erythematosus
  • Seborrheic dermatitis

Vitiligo—focus of the discussion

• Mechanism: Vitiligo is described as a chronic autoimmune skin disease in which the immune system attacks melanocytes (cells responsible for skin pigment/color).
• Result: Chronic inflammation → loss of pigment → pale spots, often first appearing in sun-exposed areas (face, hands, feet).
• Why it happens: Presented as multifactorial, not caused by a single factor:
  • Genetic susceptibility (higher risk with family history)
  • Environmental factors, including:
    • Oxidative stress
    • Exposure to toxins/chemicals/medications
  • Severe emotional stress
    • Dr. El-Qadi references studies in the USA involving over 10,000 patients, suggesting a major life event can trigger or worsen vitiligo
  • Stress and certain infections (also mentioned as contributing factors)

Autoimmune skin disease prevalence in Egypt/Africa

• Dr. El-Qadi states that in Egypt and Mediterranean/northern Africa, vitiligo is common.
• She also notes other common conditions in the region:
  • Psoriasis
  • Lichen planus
  • Pemphigus vulgaris
• Vitiligo can occur at any age, but is most common before age 30.

Historical note (Egyptian early recognition/treatment)

• The ancient Egyptians are claimed to be the first to diagnose and treat vitiligo.
• Reference is made to the Ebers Papyrus (over 2,500 years old) describing 300+ medical conditions.
• Traditional treatment examples mentioned:
  • Ancient Egyptians: mixture of oil, honey, and tar
  • Greeks: volcanic ashes with olive oil and honey
  • Indians: certain plants mixed with honey and other ingredients
• These remedies are described as helpful to some extent, but not definitive cures.

Treatment reality: cure vs management

• The segment addresses the misconception that autoimmune diseases can never be treated and that only symptoms can be controlled.
• Key points:
  • Most autoimmune diseases are chronic or recurring, with flares/relapses.
  • Even without a “definitive cure,” treatments can:
    • Control disease
    • Manage symptoms
    • Sometimes achieve remission
• Psoriasis: Advanced treatments (including biologics and topical/oral/injectable options) are said to potentially achieve 100% skin clearance.
• Vitiligo:
  • No cure is claimed in the discussion.
  • An FDA-approved topical JAK inhibitor (approved in 2022) is described as producing repigmentation rates near >90% for the face and other body parts.
  • Another systemic (oral) JAK inhibitor is said to have been approved in Europe.

How patients should approach living with vitiligo (behavioral guidance)

Dr. El-Qadi emphasizes:

• Awareness
• Managing emotional and physical stress
• Seeing a dermatologist experienced in autoimmune skin diseases (not all dermatologists specialize in these)
• Early and accurate diagnosis
• Starting treatment early and being consistent, especially for areas harder to repigment like hands and feet
• Consistency warning:
  • If treatment is stopped, there is an estimated ~40% chance of relapse within the first year.
  • She compares this to diabetes medication: even when controlled, you should not stop.
• Skin bleaching suggestion:
  • “Bleaching” is described as a last resort if other options fail (not first-line).

Mental health and social stigma

• Dr. El-Qadi stresses that mental health matters in vitiligo:
  • Studies suggest patients may experience anxiety, depression, and social stigma
  • Increased visibility can raise the overall disease burden

Correcting contagiousness myths and promoting empathy

• Another major misconception: Autoimmune skin diseases are not contagious, including vitiligo and psoriasis.
• Patients may worry about everyday interactions (e.g., handshakes).
• Community message:
  • Don’t stare
  • Be thoughtful and empathetic to reduce social harm

---

Methodology / instruction-style guidance

For patients living with vitiligo / autoimmune skin disease

• Seek awareness about the condition.
• Manage stress (emotional and physical).
• Choose the right specialist:
  • Visit a dermatologist with experience in autoimmune skin diseases
• Get an early, accurate diagnosis to improve outcomes.
• Start treatment early, especially for lesions on hands/feet (more resistant).
• Take treatment exactly as prescribed.
• Stay consistent and do not stop once improved:
  • Even if repigmentation becomes complete, stopping increases relapse risk.
• If considering cosmetic options:
  • “Bleaching” should be a last resort, not first-line.

For clinicians / families / community (social approach)

• Treat the condition as non-contagious.
• Avoid staring and reduce stigma.
• Encourage supportive behavior to lessen mental-health impact.

---

Speakers / sources featured

Speakers

• Dr. Amal El-Qadi — dermatologist specializing in autoimmune skin diseases; member of the Euro Academy of Dermatology and Venereology; expert in clinical drug development and medical affairs in the United States.
• Lubna (Lobna) — host/interviewer (appears as “Lubna” / “Lobna” on-screen).

Sources / references mentioned

• Ebers Papyrus — ancient Egyptian medical text referenced as >2,500 years old
• FDA-approved vitiligo treatment (2022) — described as a topical JAK inhibitor
• Europe-approved systemic (oral) JAK inhibitor — mentioned generally (no specific brand named)
• Studies in the USA — referenced as involving over 10,000 vitiligo patients